For Geert Wenes, the National Center for Genome Resources is, as Goldilocks would say, just right. NCGR is not intent on an immediate return on investments like many large corporations, but the research is not as open-ended as in the academic world.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.
Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.
NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.
In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.